Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-401-1S in moderate to severe ulcerative colitis
NCT04596293Phase 2Completed
- Sponsor
- Bridge Biotherapeutics
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of BBT-401 in ulcerative colitis (UC), sponsored by Bridge Biotherapeutics. Started Jun 2021; status: completed.
02
Drugs
BBT-401
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04596293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596293.